AI Summary
✦ ClarthaPrice Forecast
Probabilistic Range
Probabilistic lognormal cone using 1Y realized volatility and analyst-target drift when available.
Revenue Forecast
₹ CrEPS Forecast
₹ / shareMulti-factor synthesis of 5 key dimensions
From 30 analysts
Fundamentals
Fundamentals institutional score is 59 using EVA spread proxy 6.3%; growth durability 18.7.
Valuation
Valuation institutional score is 3 using relative multiple z-scores where peer dispersion is available.
Analyst Consensus
Analyst View institutional score is 26 using mean target upside -4.5%; dispersion penalty 24.1; recommendation breadth from available consensus.
Technical Structure
Technicals institutional score is 77 using EMA-20 continuation within 5% tolerance; VCP range/volume contraction proxy.
Market Sentiment
Recent news flow is balanced or not decisive enough to tilt the tape. Based on 3 recent ticker-linked news items.
Signal Summary
Market intelligence remains Mixed. technical structure provide support, while valuation and analyst consensus remain considerations.
Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.
Key Data Points
Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.
Valuation Metrics
Trading 20.9% above historical median. Valuation is stable — currently in the strongly overvalued zone (z-score: +1.42). Confidence: 83%.
Live forward EPS implies next-12-month EPS of ₹47.15. Applying the stock's normalized valuation corridor produces a fair range of ₹825.60 to ₹941.11, with base value near ₹889.72 (-22.3% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹47.15
Forward P/E
24.3x
Base Fair Value
₹889.72
Fair Range
₹825.60 - ₹941.11
Upside To Base
-22.3%
Estimate Source
Live forward EPS
Growth Estimate
+8.7%
5Y Average
14.71
Current
22.82
Overvalued
19.96
Undervalued
17.51
5Y Average
11.03
Current
17.11
Overvalued
14.51
Undervalued
6.95
5Y Average
2.71
Current
4.20
Overvalued
3.56
Undervalued
1.71
Peers & Comparison
Sector: Health Care · Theme: Pharmaceuticals
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
CIPLA LTD CIPLAPharmaceuticals | +3.5% | 12.0% | 35.2x Undervalued | -23% vs avg | -2.7% |
LUPIN LIMITED LUPINPharmaceuticals | +32.0% | 18.5% | 19.0x Undervalued | -58% vs avg | +21.5% |
TORRENT PHARMACEUTICALS L TORNTPHARMPharmaceuticals | +54.8% | 13.9% | 78.7x Premium | +72% vs avg | +36.2% |
GLENMARK PHARMACEUTICALS GLENMARKPharmaceuticals | +23.1% | 10.1% | 35.4x Undervalued | -23% vs avg | +11.2% |
ABBOTT INDIA LIMITED ABBOTINDIAPharmaceuticals | +6.5% | 22.4% | 37.8x Undervalued | -17% vs avg | -15.6% |
LAURUS LABS LIMITED LAURUSLABSPharmaceuticals | +29.1% | 15.0% | 91.4x Premium | +100% vs avg | +121.8% |
AJANTA PHARMA LIMITED AJANTPHARMPharmaceuticals | +24.8% | 19.6% | 38.6x Undervalued | -16% vs avg | +31.7% |
DR. REDDY S LABORATORIES DRREDDYPharmaceuticals | -5.6% | 10.0% | 29.2x Undervalued | -36% vs avg | -3.9% |
ZYDUS LIFESCIENCES LTD trades at a discount (22.3x vs peer avg 45.7x), suggesting potential undervaluation relative to the Pharmaceuticals cohort. Peers include CIPLA LTD, LUPIN LIMITED, TORRENT PHARMACEUTICALS L — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹2.28K CrDec 2025Latest net profit
₹357 CrDec 2025Latest EPS
₹2.95Dec 2025Net margin
-4.1%Dec 2025Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Dec 2025
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,579 | 2,956 | 2,159 | 2,371 | 3,332 | 4,160 | 2,621 | 2,516 | 5,820 | 2,588 | 2,871 | 2,284 |
| Expenses | 1,766 | 1,778 | 1,597 | 1,689 | 1,771 | 1,782 | 1,733 | 2,078 | 1,996 | 2,039 | 2,115 | 2,233 |
| Operating Profit | 693 | 1,056 | 438 | 555 | 1,431 | 2,248 | 754 | 306 | 3,696 | 419 | 620 | -94.1 |
| OPM % | 26.88% | 35.74% | 20.28% | 23.39% | 42.94% | 54.03% | 28.77% | 12.15% | 63.5% | 16.2% | 21.6% | -4.12% |
| Other Income | 251 | 82.4 | 621 | 124 | 369 | 107 | 381 | 289 | 185 | 193 | 937 | 623 |
| Interest | 126 | 126 | 90.9 | 104 | 106 | 121 | 95.9 | 97.2 | 206 | 138 | 114 | 116 |
| Depreciation | 120 | 121 | 125 | 128 | 131 | 131 | 134 | 132 | 128 | 130 | 136 | 144 |
| Profit before tax | 819 | 1,012 | 968 | 574 | 1,694 | 2,234 | 1,039 | 497 | 3,675 | 475 | 1,444 | 412 |
| Tax % | 15.18% | 22.87% | 16.85% | 21.57% | 16.52% | 23.85% | 24.01% | 10.22% | 23.43% | 18.99% | 19.88% | 13.55% |
| Net Profit | 694 | 781 | 805 | 450 | 1,414 | 1,701 | 790 | 446 | 2,814 | 385 | 1,157 | 357 |
| EPS in Rs | 4.85 | 7.71 | 7.96 | 4.45 | 13.89 | 16.90 | 7.85 | 4.68 | 27.96 | 3.82 | 11.49 | 2.95 |
All values in Rs. Crore unless otherwise stated. Source: CMIE Prowess, Quarterly Interim Standalone.